Sera Prognostics (NASDAQ:SERA) CEO Sells $66,647.70 in Stock

Key Points

• Sera Prognostics CEO Zhenya Lindgardt sold 21,158 shares of stock for a total of $66,647.70, reducing their ownership by 2.54% to 811,136 shares.
• Following the CEO's sale, Sera Prognostics' stock price dropped by 2.2% to $3.10, and the company has a market capitalization of $116.78 million.
• Wall Street analysts have downgraded Sera Prognostics from a "hold" rating to a "sell" rating, reflecting concerns over the company's financial performance.

Sera Prognostics, Inc. (NASDAQ:SERA - Get Free Report) CEO Zhenya Lindgardt sold 21,158 shares of the business's stock in a transaction dated Tuesday, September 9th. The stock was sold at an average price of $3.15, for a total transaction of $66,647.70. Following the completion of the sale, the chief executive officer owned 811,136 shares in the company, valued at approximately $2,555,078.40. This trade represents a 2.54% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Sera Prognostics Stock Down 2.2%

Sera Prognostics stock traded down $0.07 during midday trading on Tuesday, hitting $3.10. The company's stock had a trading volume of 74,640 shares, compared to its average volume of 104,642. The stock's 50-day moving average price is $2.77 and its 200-day moving average price is $2.88. Sera Prognostics, Inc. has a 12 month low of $1.37 and a 12 month high of $9.13. The company has a market capitalization of $116.78 million, a PE ratio of -3.65 and a beta of 1.00.

Sera Prognostics (NASDAQ:SERA - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($0.16) earnings per share for the quarter, topping analysts' consensus estimates of ($0.21) by $0.05. The firm had revenue of $0.02 million for the quarter, compared to analysts' expectations of $0.05 million. Sera Prognostics had a negative return on equity of 45.86% and a negative net margin of 30,306.48%. As a group, equities analysts anticipate that Sera Prognostics, Inc. will post -0.96 EPS for the current year.

Wall Street Analyst Weigh In

Separately, Wall Street Zen cut Sera Prognostics from a "hold" rating to a "sell" rating in a research note on Saturday, August 9th.

Institutional Investors Weigh In On Sera Prognostics

Several large investors have recently made changes to their positions in the company. Corient Private Wealth LLC grew its stake in shares of Sera Prognostics by 73.9% in the 2nd quarter. Corient Private Wealth LLC now owns 100,000 shares of the company's stock valued at $277,000 after buying an additional 42,500 shares in the last quarter. Captrust Financial Advisors grew its stake in shares of Sera Prognostics by 20.0% in the 2nd quarter. Captrust Financial Advisors now owns 602,277 shares of the company's stock valued at $1,668,000 after buying an additional 100,366 shares in the last quarter. Qube Research & Technologies Ltd bought a new stake in shares of Sera Prognostics in the 2nd quarter valued at approximately $92,000. Riverview Capital Advisers LLC bought a new stake in shares of Sera Prognostics in the 2nd quarter valued at approximately $35,000. Finally, Y Intercept Hong Kong Ltd bought a new stake in shares of Sera Prognostics in the 2nd quarter valued at approximately $188,000. Institutional investors own 54.64% of the company's stock.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.